Therapeutic Index

Educational content, not medical advice. Dosing and drug monitoring decisions must be individualized by a qualified clinician.

Two curves, one ratio

Every drug does two things as you increase the dose: it produces more of the effect you want, and eventually it produces toxicity. Plot each of these as a quantal dose-response curve — the percentage of a population that shows the response at each dose — and you get two sigmoid curves marching rightward across the dose axis. The desired-effect curve sits on the left; the toxicity curve sits on the right. The horizontal distance between them is the safety margin.

The therapeutic index collapses that distance into a single number by comparing the midpoints of the two curves. The ED50 (median effective dose) is the dose at which half the population gets the desired effect. The TD50 (median toxic dose) is the dose at which half the population shows the defined toxicity. The therapeutic index is simply:

TI = TD50 / ED50

In animal toxicology, where a hard endpoint is needed, the median lethal dose LD50 replaces TD50, giving the original form coined by Paul Ehrlich a century ago: TI = LD50/ED50. A drug with an LD50 of 1000 mg/kg and an ED50 of 10 mg/kg has a therapeutic index of 100 — you would need a hundredfold overdose, on average, before lethality matched efficacy. A drug with an LD50 of 30 mg/kg and the same ED50 has an index of 3, and that is a drug you watch carefully.

Index, margin, and window — three related ideas

These terms are often used loosely, but each has a precise job. The therapeutic index is the ratio of two median doses: it describes the drug in the abstract and is a single dimensionless number. The therapeutic window (or therapeutic range) is the band of plasma concentrations — measured in ng/mL, µg/mL, or mEq/L — that is high enough to be effective but low enough to avoid toxicity; this is what the clinician actually targets when adjusting a dose. The margin of safety is a stricter version of the index that looks at the tails of the curves rather than the medians.

The reason the tails matter is that the index based on medians can be dangerously reassuring when the two curves have different slopes. If the toxicity curve is shallow, a few unusually sensitive patients may experience harm at a dose far below the TD50, even though the medians look comfortably separated. The certain safety factor, LD1/ED99, addresses this: it compares the dose that is lethal to just 1% of subjects against the dose that is effective in 99% of them. When LD1/ED99 is greater than 1, even the most sensitive responders are protected from the toxic threshold; when it drops below 1, the effective and toxic populations overlap.

Therapeutic index versus therapeutic window

Feature	Therapeutic index (TI)	Therapeutic window
What it measures	Ratio of toxic dose to effective dose	Range of safe, effective plasma concentrations
Units	Dimensionless ratio	Concentration (ng/mL, µg/mL, mEq/L)
Formula	TD50 / ED50 (or LD50 / ED50)	Lower effective level → upper toxic level
Scope	The drug, in general	Targeting in an individual patient
Clinical use	Classifying a drug's relative safety	Therapeutic drug monitoring and dose titration
Example value	Digoxin TI ≈ 2-3	Digoxin 0.5-2.0 ng/mL

Narrow therapeutic index drugs

A drug is called a narrow therapeutic index (NTI) drug when the effective and toxic concentrations sit close together — by various regulatory definitions, when the index is small enough that ordinary variation in dose or pharmacokinetics can produce serious toxicity. These are the drugs that fill the therapeutic-drug-monitoring section of a clinical chemistry lab, and the U.S. FDA applies tighter bioequivalence limits when a generic version is substituted for the brand.

• Warfarin. Anticoagulation is monitored by the INR, with a typical target of 2.0-3.0. Below it, clots; above it, hemorrhage. Diet, antibiotics, and CYP2C9/VKORC1 genotype all shift the dose-response.
• Digoxin. Therapeutic at 0.5-2.0 ng/mL; toxicity (nausea, visual halos, arrhythmias) climbs above 2 ng/mL and is worsened by hypokalemia and renal impairment.
• Lithium. Target 0.6-1.2 mEq/L; tremor, confusion, and seizures appear above 1.5 mEq/L. Dehydration and NSAIDs raise levels sharply.
• Phenytoin. Target total level 10-20 µg/mL, with saturable (zero-order) kinetics meaning a small dose increase can cause a large jump in concentration.
• Aminoglycosides and vancomycin. Effective antibacterial peaks must be balanced against nephro- and ototoxicity; both peak and trough levels are tracked.
• Theophylline, methotrexate, tacrolimus, cyclosporine. Each pairs a useful effect with a steep toxicity curve and demands monitoring.

Contrast these with wide-index drugs. Penicillin's therapeutic index can exceed 100; you can give grams more than needed with little consequence, which is why it is dosed by simple weight-based rules rather than blood levels. The whole point of the index is to tell you which category a drug falls into.

Why a narrow index is dangerous in real patients

The intrinsic ratio belongs to the molecule, but the effective safety margin in front of you belongs to the patient. Several physiologic levers move a patient closer to the toxic edge even when the prescribed dose is unchanged:

• Reduced clearance. Renal failure raises plasma levels of digoxin, lithium, and aminoglycosides; hepatic failure does the same for drugs cleared by the liver. Falling clearance silently shrinks the window.
• Protein binding. Phenytoin is ~90% albumin-bound; only the free fraction is active. Low albumin (illness, malnutrition) raises free drug even when the measured total looks normal — hence the use of free phenytoin levels.
• Electrolytes. Hypokalemia and hypomagnesemia sensitize cardiac tissue to digoxin, lowering the toxic threshold without any change in serum digoxin.
• Drug interactions. Inhibition of cytochrome P450 enzymes or P-glycoprotein transporters slows elimination and can double a plasma level. Amiodarone, for instance, raises both warfarin and digoxin levels.
• Genetics, age, and pregnancy. Pharmacogenetic variation in metabolism, the reduced organ reserve of older patients, and the expanded volume of distribution in pregnancy all reshape where a given dose lands on the curve.

This is why narrow-index drugs are dosed to a measured plasma level rather than a fixed milligram amount, and why a hospital tracks them so closely. The therapeutic index predicts how much trouble is possible; therapeutic drug monitoring keeps the individual patient inside the safe band.

Wide-index versus narrow-index drugs at a glance

How safety margin changes clinical practice

Property	Wide therapeutic index	Narrow therapeutic index
Approximate TI	> 10 (penicillin > 100)	~ 1-3 (digoxin, lithium, warfarin)
Gap between ED and TD	Large — forgiving	Small — unforgiving
Blood-level monitoring	Rarely needed	Routine and essential
Effect of mild renal impairment	Usually tolerated	Can precipitate toxicity
Generic substitution	Standard bioequivalence rules	Tighter FDA bioequivalence limits
Dosing approach	Fixed or weight-based	Titrated to measured level

The clinical bottom line

• One ratio, big consequences. The therapeutic index is TD50/ED50 — the higher the number, the safer the drug.
• Medians can mislead. When the toxicity curve is shallow, prefer the certain safety factor LD1/ED99 to capture the vulnerable tail.
• Index is the drug; window is the patient. A narrow index is a warning to monitor plasma concentrations and keep the patient inside the therapeutic range.
• Physiology moves the margin. Kidney and liver function, albumin, electrolytes, interactions, and genetics all shift where a fixed dose lands.
• Narrow-index drugs to respect: warfarin, digoxin, lithium, phenytoin, theophylline, aminoglycosides, methotrexate, tacrolimus.